Study of Immune Response During Pelvic Radiation and Brachytherapy in Cervical Cancer Patients Observing Effects of Different Radiation Doses and Techniques

What this Trial Is About

Researchers are studying how pelvic andor para-aortic radiotherapy affects both local tumor immunity and the overall immune response in people with cervical cancer. The goal is to understand how different radiation doses, fraction sizes, and treatment areas impact immune activity, which could help improve radiation quality, reduce cancer recurrence, and enhance survival outcomes. This observational study focuses on immune system changes related to cervical cancer treatment. Participants will be grouped according to their radiation treatment plans, which include various radiation doses and fractionation schedules. Blood and tumor samples will be collected at multiple time points depending on the treatment cohort. The study will analyze PD-L1 expression in tumor biopsies before and after treatment, as well as immune cell profiles using flow cytometry from blood and tumor tissues. Radiation treatment details such as dose volumes and organ doses will also be recorded and analyzed. Throughout the study, participants will provide blood and tumor tissue samples at designated times, and existing blood test data will be reviewed. Researchers will use statistical methods to compare immune responses across different radiation plans and time points. The study aims to measure systemic immune responses and tumor-infiltrating immune cells over three years, along with tracking disease-free survival for up to three years after treatment. This comprehensive monitoring helps to evaluate the interaction between radiation therapy and immune changes in cervical cancer patients.

Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer